Nachrichten zur Bristol-Myers Squibb Co Aktie

Opdivo delivers superior five-year survival results in renal cell carcinoma

The company said that 26% of patients with previously treated advanced or metastatic renal cell carcinoma are alive at five…

Better Buy: GlaxoSmithKline vs. Bristol-Myers Squibb

Which of these top pharma stocks is the better buy right now?...…

Better Buy: Biogen vs. Bristol-Myers Squibb

Does the potential of a home run for Biogen with its Alzheimers disease candidate outweigh the strong lineup and pipeline…

Bristol-Myers (BMY) CAR T Cell Therapy Gets Priority Review

Bristol-Myers (BMY) BLA for lisocabtagene maraleucel gets Priority Review from the FDA....…

The US FDA accepts for priority review Bristol-Myers Squibbs BLA for liso-cel for adult patients with relapsed or refractory large B-cell lymphoma

The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of August 17, 2020. "There remains a…

FDA Gives Bristol-Myers Squibbs CAR-T Liso-Cel a Priority Review

A decision on the cancer therapy is expected by Aug. 17....…

Bristol-Myers Squibbs liso-cel fast tracked in U.S. for large B-cell lymphoma

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Building A Hedged Portfolio Around Bristol-Myers Squibb

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

The Zacks Analyst Blog Highlights: Alibaba, Toyota Motor, Bristol-Myers Squibb, S&P Global and Uber Technologies

The Zacks Analyst Blog Highlights: Alibaba, Toyota Motor, Bristol-Myers Squibb, S&P Global and Uber Technologies...…

Bristol-Myers Squibb Stock Is Too Cheap to Ignore

The acquisition of Celgene is working wonders so far....…

Sell-siders on board with Bristol-Myers Squibbs Q4 & outlook

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

This is Why Bristol-Myers Squibb (BMY) is a Great Dividend Stock

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy…

Pharma Stock Roundup: BMY, GSK, SNY Q4 Results, MRK Earnings & Split

Merck (MRK), Bristol Myers (BMY), Sanofi (SNY), Glaxo (GSK) and Novo Nordisk (NVO) announce Q4 results....…

Bristol-Myers (BMY) Q4 Earnings & Revenues Beat Estimates

Bristol-Myers (BMY) beats both earnings and sales estimates in the fourth quarter, primarily on robust sales of Eliquis and acquisition…

Bristol-Myers Squibb Co (BMY) Q4 2019 Earnings Call Transcript

BMY earnings call for the period ending December 31, 2019....…

Bristol-Myers Squibb and Merck going opposite ways with PD-1 inhibitors

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Bristol-Myers Squibbs Earnings Get a Boost From Celgene Acquisition

The pharmaceutical giants guidance also looks good....…

Bristol-Myers Squibb Company 2019 Q4 - Results - Earnings Call Presentation

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

UPDATE 1-Bristol-Myers earnings rise due to Celgene contribution

Bristol-Myers Squibb Co said on Thursday its operating profit rose by around a third from a year ago because fourth-quarter results included…

How Bristol-Myers Squibb Trounced Wall Streets Q4 Estimates

In a word: Celgene....…

Bristol-Myers Squibb schreibt nach Celgene-Kauf im Schlussquartal Verlust

NEW YORK (dpa-AFX) - Nach der Übernahme des Biopharmaspezialisten Celgene hat der Pharmakonzern Bristol-Myers Squibb im vierten Quartal einen Verlust…

Bristol-Myers Squibb schreibt nach Celgene-Kauf im Schlussquartal Verlust

NEW YORK (dpa-AFX) - Nach der Übernahme des Biopharmaspezialisten Celgene hat der Pharmakonzern Bristol-Myers Squibb …

Bristol-Myers: Celgene-Übernahme zahlt sich aus

Bristol-Myers: Celgene-Übernahme zahlt sich aus...…

Bristol-Myers +3% premarket on Q4 beat

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Bristol-Myers Squibb reports 33% jump in Q4 revenue, Opdivo sales fall 2%

Shares of Bristol-Myers Squibb were up 2% in premarket trading on Thursday after the company beat earnings estimates for…

Bristol-Myers Tops Q4 Earnings Forecast As Celgene Takeover Boosts Bottom Line

Um den gesamten Artikel unter thestreet.com zu lesen, klicken Sie bitte auf die Überschrift...…

Bristol-Myers earnings rise due to Celgene deal

Bristol-Myers Squibb Co said on Thursday its operating profit rose by around a third from a year ago because fourth-quarter results included…

Bristol-Myers Squibb EPS beats by $0.28, beats on revenue

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

What Are Bristol-Myers Squibbs Top 3 Drugs-

Bristol-Myers Squibbs top 3 selling drugs (excluding that of Celgene) are Eliquis, Opdivo, and Orencia. These three drugs combined, likely…

Bristol-Myers Squibb, BioMotiv launch new biotechnology firm Anteros Pharmaceuticals

Yale University has developed the intellectual property behind Anteros and was first in-licenced by BMS and later authorised to Anteros.…

Bristol-Myers: Buy At The Highs

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Will Opdivo & Eliquis Drive Bristol-Myers (BMY) Q4 Earnings-

Investors will focus on the performance of Opdivo, Revlimid and Eliquis along with the regular top and bottom-line numbers when…

Bristol-Myers and BioMotiv launch new drug venture

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Bristol-Myers Opdivo-Yervoy NSCLC Application in EU Withdrawn

Bristol-Myers (BMY) has withdrawn its application in the EU for the Opdivo and Yervoy combo for the treatment of advanced…

Factors Setting the Tone for Bristol-Myers (BMY) Q4 Earnings

Investors will focus on regular top and bottom-line numbers along with key pipeline updates when Bristol-Myers (BMY) reports fourth-quarter results....…

The Week Ahead In Biotech: Merck, Bristol-Myers Earnings, Conference Presentations In Focus

Biotech stocks see-sawed through the week ended Jan. 31 and ended the month lower overall. Big pharma earnings of the…

Bristol-Myers Withdraws European Application for Lung Cancer Combo

Regulators said its impossible to evaluate the drug with so many clinical trial alterations....…

UPDATE 2-Bristol-Myers pulls Opdivo+Yervoy lung application in Europe

Drugmaker Bristol-Myers Squibb Co said on Friday it was pulling the application to have its immunotherapies Opdivo and Yervoy approved in Europe…

CORRECTED-Bristol-Myers pulls Opdivo+Yervoy lung application in Europe

Drugmaker Bristol-Myers Squibb Co said on Friday it was pulling the application to have its immunotherapies Opdivo and Yervoy approved in Europe…

CORRECTED-UPDATE 1-Bristol-Myers Squibb pulls Opdivo+Yervoy lung application in Europe

Drugmaker Bristol-Myers Squibb Co said on Friday it was pulling the application to have its immunotherapies Opdivo and Yervoy approved in Europe…

Bristol-Myers Squibb withdraws European application for O+Y for lung cancer

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Bristol-Myers pulls Opdivo+Yervoy lung application in Europe

Drugmaker Bristol Myers Inc said on Friday it was pulling the application to have its immunotherapies Opdivo and Yervoy approved in Europe…

UPDATE 1-Bristol-Myers pulls Opdivo+Yervoy lung application in Europe

Drugmaker Bristol Myers Inc said on Friday it was pulling the application to have its immunotherapies Opdivo and Yervoy approved in Europe…

ServiceNow CEO Bill McDermott talks earnings results and 2020 guidance

John Donahoe, ServiceNow CEO, discusses the company's quarterly earnings, first-quarter guidance, taking on new customers such as Bristol-Myers Squibb and…

3 Stocks With Rising Prices That Still Look Cheap

A search for healthy companies bucking the trend toward high P/Es turned up only a handful of names. How Discovery,…

Bristol-Myers Squibb (BMY) Outpaces Stock Market Gains: What You Should Know

Bristol-Myers Squibb (BMY) closed the most recent trading day at $64.81, moving +1.74% from the previous trading session....…

Bristol-Myers: A Blue Chip Name Worth Buying During the Coronavirus Scare

Um den gesamten Artikel unter thestreet.com zu lesen, klicken Sie bitte auf die Überschrift...…

Bristol-Myers Squibb: Strong Quality And Attractive Valuation

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Bristol-Myers Squibb is planning to launch 8 drugs in 18 months for everything from cancer to multiple sclerosis. Heres what they are and how the $150 billion pharma giant plans to pull it off.

The newly combined Bristol-Myers Squibb and Celgene is shaping up to be a formidable company in the pharmaceutical industry.  Its now…

An Emboldened Bristol-Myers Squibb Wants $1.5 Billion From Gilead Sciences

A jury that told Gilead Sciences to pay $752 million worth of patent infringement damages didnt go as far as…